Literature DB >> 19750575

Baseline predictors of virological response for chronic hepatitis B patients.

Xue-Jie Wu1, Yan Wang, Ji Chen, Gui-Qiang Wang.   

Abstract

AIM: To determine which baseline factors of chronic hepatitis B patients are predictive of virological response to Peginterferon alpha-2b therapy.
METHODS: A total of 21 HBeAg-positive chronic hepatitis B (CHB) patients treated with Peginterferon alpha-2b were recruited. They were treated with Peginterferon alpha-2b (0.5-1.0 microg/kg per week) for 24 wk and followed up for 24 wk. Clinical and laboratory data of the patients were determined at pretreatment and at week 12, at 24 during treatment, and at week 48 during follow up.
RESULTS: Ten patients achieved a virological response at the end of treatment. Their baseline serum alanine aminotransferase (ALT), thyroid-stimulating hormone (TSH), and total thyroxin (TT4) levels were significantly different from those who failed treatment. The positive predictive values (PPV) and negative predictive values (NPV) of ALT, TSH, and TT4 were 75% and 89 %, 75% and 89 %, and 75% and 75%, respectively. Moreover, combinations of the baseline ALT and TT4, ALT and TSH, TT4 and TSH levels had much higher PPV and NPV (86% and 88%, 89% and 100%, 83% and 100%, respectively).
CONCLUSION: Baseline serum ALT, TSH, and TT4 levels, especially in combination, have high predictive values of virological response to Peginterferon alpha-2b in HBeAg-positive CHB patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19750575      PMCID: PMC2744188          DOI: 10.3748/wjg.15.4311

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

1.  Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B.

Authors:  J M Sánchez-Tapias; J Costa; A Mas; A Parés; M Bruguera; J Rodés
Journal:  J Hepatol       Date:  1988-02       Impact factor: 25.083

2.  Hepatitis B genotypes and the response to interferon therapy.

Authors:  J H Kao; N H Wu; P J Chen; M Y Lai; D S Chen
Journal:  J Hepatol       Date:  2000-12       Impact factor: 25.083

3.  A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.

Authors:  M-F Yuen; H-J Yuan; C-K Hui; D K-H Wong; W-M Wong; A O-O Chan; B C-Y Wong; C-L Lai
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 4.  Hepatitis B viral genotypes: clinical relevance and molecular characteristics.

Authors:  Jia-Horng Kao
Journal:  J Gastroenterol Hepatol       Date:  2002-06       Impact factor: 4.029

5.  A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Authors:  Guang-Bi Yao; Zhen-Yu Cui; Bao-En Wang; Ji-Lu Yao; Min-De Zeng
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2004-05

6.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C.

Authors:  Chun Tao Wai; Chi-Jen Chu; Munira Hussain; Anna S F Lok
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

7.  Immunomodulatory role of thyroid hormones: in vivo effect of thyroid hormones on the blastogenic response of lymphoid tissues.

Authors:  S Chatterjee; A S Chandel
Journal:  Acta Endocrinol (Copenh)       Date:  1983-05

8.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

Authors:  Michael W Fried; Teerha Piratvisuth; George K K Lau; Patrick Marcellin; Wan-Cheng Chow; Graham Cooksley; Kang-Xian Luo; Seung Woon Paik; Yun-Fan Liaw; Peter Button; Matei Popescu
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

9.  Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Authors:  Rami Moucari; Vincent Mackiewicz; Olivier Lada; Marie-Pierre Ripault; Corinne Castelnau; Michelle Martinot-Peignoux; Agnes Dauvergne; Tarik Asselah; Nathalie Boyer; Pierre Bedossa; Dominique Valla; Michel Vidaud; Marie-Hélène Nicolas-Chanoine; Patrick Marcellin
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Involvement of thyroid hormones in the alterations of T-cell immunity and tumor progression induced by chronic stress.

Authors:  Luciana Romina Frick; Maximiliano Rapanelli; Ursula Agnes Bussmann; Alicia Juana Klecha; Maria Laura Barreiro Arcos; Ana Maria Genaro; Graciela Alicia Cremaschi
Journal:  Biol Psychiatry       Date:  2009-01-23       Impact factor: 13.382

View more
  1 in total

1.  Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers.

Authors:  Bushra Ijaz; Waqar Ahmad; Fouzia T Javed; Sana Gull; Sajida Hassan
Journal:  Virol J       Date:  2011-02-27       Impact factor: 4.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.